Cognition Therapeutics Inc (NASDAQ:CGTX) has a beta value of 1.00 and has seen 1.5 million shares traded in the recent trading session. The company, currently valued at $25.02M, closed the recent trade at $0.40 per share which meant it lost -$0.02 on the day or -4.06% during that session. The CGTX stock price is -637.5% off its 52-week high price of $2.95 and 15.0% above the 52-week low of $0.34. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.54 million shares traded. The 3-month trading volume is 1.60 million shares.
The consensus among analysts is that Cognition Therapeutics Inc (CGTX) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.12.
Cognition Therapeutics Inc (NASDAQ:CGTX) trade information
Sporting -4.06% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CGTX stock price touched $0.40 or saw a rise of 18.35%. Year-to-date, Cognition Therapeutics Inc shares have moved -42.44%, while the 5-day performance has seen it change -12.11%. Over the past 30 days, the shares of Cognition Therapeutics Inc (NASDAQ:CGTX) have changed -6.20%. Short interest in the company has seen 1.42 million shares shorted with days to cover at 0.5.
Cognition Therapeutics Inc (CGTX) estimates and forecasts
The company’s shares have lost -4.06% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -16.44% over the past 5 years. Earnings growth for 2025 is a modest 52.79% while over the next 5 years, the company’s earnings are expected to increase by 26.97%.
CGTX Dividends
Cognition Therapeutics Inc is expected to release its next earnings report on 2025-Mar-19 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cognition Therapeutics Inc (NASDAQ:CGTX)’s Major holders
Insiders own 2.24% of the company shares, while shares held by institutions stand at 17.89% with a share float percentage of 18.30%. Investors are also buoyed by the number of investors in a company, with Cognition Therapeutics Inc having a total of 46.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 1.15 million shares worth more than $1.9 million. As of 2024-06-30, VANGUARD GROUP INC held 3.4016% of shares outstanding.
The other major institutional holder is AWM INVESTMENT COMPANY, INC., with the holding of over 0.65 million shares as of 2024-06-30. The firm’s total holdings are worth over $1.08 million and represent 1.6224% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund. As of Dec 31, 2024, the former fund manager holds about 1.63% shares in the company for having 1.01 shares of worth $0.41 million while later fund manager owns 200.58 shares of worth $81995.0 as of Dec 31, 2024, which makes it owner of about 0.32% of company’s outstanding stock.
